Literature DB >> 10770653

Transient hyperphosphatasemia--where do we stand?

S Kutílek1, M Bayer.   

Abstract

Transient hyperphosphatasemia of infancy and early childhood (THI) is characterized by transiently increased serum activity of alkaline phosphatase (S-ALP), predominantly its bone or liver isoform, in children under five years of age. There are no signs of metabolic bone disease or hepatopathy corresponding with the increased SALP, nor is there a disease common to all children with THI. To date, THI has been reported in more than 400 children. Viral etiology of THI has been proposed; transiently increased bone turnover and impaired clearance of ALP from the serum were originally considered as its causes. The pathogenesis is most probably multifactorial. THI is a benign disorder, as prospective follow-up of children with a history of TH revealed normal growth and normal bone density. Children with TH should be spared from excessive diagnostic procedures.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10770653

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  5 in total

1.  Erroneous diagnosis of rickets.

Authors:  Stepan Kutilek; Sylva Skalova
Journal:  Turk Pediatri Ars       Date:  2017-09-01

2.  Benign transient hyperphosphatasemia in an infant during zinc supplementation.

Authors:  Ayça Bilge Sönmez; İlter Arifoğlu; Ahmet Yıldırım; Filiz Tütüncüler
Journal:  Turk Pediatri Ars       Date:  2018-06-01

3.  Normal bone turnover in transient hyperphosphatasemia.

Authors:  Stepan Kutilek; Barbora Cervickova; Pavla Bebova; Marie Kmonickova; Vladimir Nemec
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-05-03

4.  A case series of benign transient hyperphosphatasemia from a pediatric endocrinology reference health facility in Turkey.

Authors:  Fatma Dursun; Heves Kirmizibekmez
Journal:  Pan Afr Med J       Date:  2018-07-11

5.  Hepatitis during respiratory syncytial virus infection--a case report.

Authors:  Branka Kristić Kirin; Renata Zrinski Topić; Slavica Dodig
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.